NCT06363708View on ClinicalTrials.gov

Tislelizumab in Combination With Chemotherapy as a Neoadjuvant Treatment for Advanced Endometrial Cancer

NANot yet recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

June 1, 2024

Primary Completion Date

December 1, 2025

Study Completion Date

June 30, 2026

Conditions
Endometrial Neoplasms
Interventions
DRUG

Tislelizumab

Tislelizumab 200mg D1 ,Q3W

DRUG

Paclitaxel

Paclitaxel(175 mg/m2 ) D1,Q3W

DRUG

Carboplatin

Carboplatin(AUC=5) D1,Q3W

Trial Locations (3)

430014

The Central Hospital of Wuhan, Wuhan

430062

Zhongnan Hospital of Wuhan University, Wuhan

430070

Hubei maternal and child health care hospital, Wuhan

All Listed Sponsors
lead

Zhongnan Hospital

OTHER

NCT06363708 - Tislelizumab in Combination With Chemotherapy as a Neoadjuvant Treatment for Advanced Endometrial Cancer | Biotech Hunter | Biotech Hunter